This trial is active, not recruiting.

Condition multiple sclerosis (ms)
Treatments laquinimod 0.6 mg, matching placebo, laquinimod 1.2 mg
Phase phase 3
Sponsor Teva Pharmaceutical Industries
Start date February 2013
End date March 2017
Trial size 2199 participants
Trial identifier NCT01707992, LAQ-MS-305


This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod 0.6 mg/day or 1.2mg/day in subjects with RRMS.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Two capsules, one containing 0.6 mg laquinimod and the other containing matching placebo, to be administered orally once daily during both Periods 1 and 2.
laquinimod 0.6 mg
Two capsules containing 0.6 mg laquinimod to be administered orally once daily during both Periods 1 and 2. NOTE- As of January 2016, this arm has been discontinued.
laquinimod 1.2 mg
(Placebo Comparator)
Two capsules containing placebo (matching to the 0.6 mg) to be administered orally once daily during Period 1.
matching placebo

Primary Outcomes

Time to Confirmed Disease Progression (CDP) in Period 1
time frame: 24 months (Period 1)

Secondary Outcomes

Percent change in brain volume
time frame: Change from Baseline to 15 Months
The time to first confirmed relapse during Period 1
time frame: 24 months (Period 1)

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: - Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria, with relapse onset disease or a relapsing-remitting disease course. - Subjects must be ambulatory with Kurtzke EDSS score of 0- 5.5 in both screening and randomization visits. - Subjects must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or per os (PO)] or adrenocorticotrophic hormone (ACTH), 60 days prior to randomization. - Subjects must have experienced at least one documented relapse in the 12 months prior to randomization. - Subjects must be between 18 and 55 years of age at screening, inclusive. - Subjects must have disease duration of not more than 15 years. Women of child-bearing potential (for example women who are not postmenopausal or surgically sterilized) must practice an acceptable method of birth control for 30 days before taking the study drug and two acceptable methods of birth control during the duration of the study and until 30 days after the last dose of study medication. Acceptable methods of birth control include: intrauterine devices, barrier method (condom or diaphragm with spermicide) and hormonal methods of birth control (e.g. oral contraceptive, contraceptive patch, and long-acting injectable contraceptive). - Subjects must be able to sign and date a written informed consent prior to entering the study. - Subjects must be willing and able to comply with the protocol requirements for the duration of the study. Exclusion Criteria: - Subjects with progressive forms of MS. - Subjects with Neuromyelitis Optica (NMO). - Use of experimental or investigational drugs and/or participation in drug clinical studies within 6 months prior to randomization. - Use of immunosuppressive agents,or cytotoxic agents, including Cyclophosphamide within 6 months prior to randomization. - Use of either of the following within 2 years prior to screening visit: natalizumab (Tysabri®), rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab. - Use of teriflunomide (Aubagio®) within 2 years prior to randomization, except if active washout (with either cholestyramine or activated charcoal) was done 2 months or more prior to randomization. - Previous treatment with glatiramer acetate (Copaxone®) Interferon β (either 1a or 1b), fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®) or intravenous immunoglobulin (IVIG) within 2 months prior to randomization. - Chronic (more than 30 consecutive days) systemic (IV, IM or PO) corticosteroid treatment within 2 months prior to randomization. - Previous use of Mitoxantrone (Novantrone®), Cladribine, or alemtuzumab (Lemtrada®). - Previous use of laquinimod. - Previous total body irradiation or total lymphoid irradiation. - Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation. - Use of moderate/strong inhibitors of CYP3A4 within 2 weeks prior to randomization. - Use of inducers of CYP3A4 within 2 weeks prior to randomization. - Pregnancy or breastfeeding. - Serum levels ≥3x upper limit of the normal range (ULN) of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at screening - Serum direct bilirubin which is ≥2xULN at screening. - Subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests MRI or chest X-ray. Such conditions may include: - A major cardiovascular event (e.g. myocardial infarction, acute coronary syndrome, de-compensated congestive heart failure, pulmonary embolism, coronary revascularization) that occurred during the past 6 months prior to randomization. - Any acute pulmonary disorder - A CNS disorder other than MS that may jeopardize the subject's participation in the study, including such disorders that are demonstrated on the baseline MRI. - A gastrointestinal disorder that may affect the absorption of study medication. - Renal disease. - Any form of acute or chronic liver disease. - Known human immunodeficiency virus positive status. - A history of drug and/or alcohol abuse. - Unstable psychiatric disorder. - Any malignancies, excluding basal cell carcinoma, in the 5 years prior to randomization. - A known history of sensitivity to gadolinium (Gd). - GFR ≤ 60 mL/min at the screening visit. - Inability to successfully undergo MRI scanning. - Subjects who underwent endovascular treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)within 3 months prior to randomization. - Known hypersensitivity that would preclude administration of laquinimod capsule, such as hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.

Additional Information

Official title A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod (0.6 mg/d or 1.2 mg/d) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Description Eligible subjects with confirmed relapsing-remitting multiple sclerosis will be randomized in a 1:1:1 ratio into one of the following treatment arms: Laquinimod capsules 0.6 mg, Laquinimod capsules 1.2 mg and matching placebo. The study will be comprised of two treatment periods: Period 1: Double-blind Placebo-controlled (DBPC) period: not more than 24 months of once-daily, oral administration of either laquinimod 0.6 mg, 1.2 mg or matching oral placebo. The Sponsor will declare closing of Period 1 for all subjects when 260 events of confirmed disease progression (CDP) have occurred or when all ongoing enrolled subjects completed 24 months in Period 1 (whichever occurs first).
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Teva Pharmaceutical Industries.